McKesson Corporation (MCK)
| Market Cap | 47.08B |
| Revenue (ttm) | 263.97B |
| Net Income (ttm) | 1.11B |
| Shares Out | 145.36M |
| EPS (ttm) | 9.02 |
| PE Ratio | 35.92 |
| Forward PE | 13.97 |
| Dividend | $1.88 (0.58%) |
| Ex-Dividend Date | May 31, 2022 |
| Volume | 233,509 |
| Open | 331.50 |
| Previous Close | 333.16 |
| Day's Range | 322.73 - 333.86 |
| 52-Week Range | 184.43 - 339.94 |
| Beta | 0.72 |
| Analysts | Buy |
| Price Target | 358.26 (+10.6%) |
| Earnings Date | May 5, 2022 |
About MCK
McKesson Corporation provides healthcare supply chain management, retail pharmacy, community oncology and specialty care, and healthcare information solutions in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice ma...
Financial Performance
Financial StatementsAnalyst Forecast
According to 21 analysts, the average rating for MCK stock is "Buy." The 12-month stock price forecast is 358.26, which is an increase of 10.62% from the latest price.
News
7 Stock Picks to Play the Post-Pandemic Return of Dental Visits
Although Covid-19 allowed people the excuse to not see their dentist, the necessary return could benefit these dental stocks to buy. The post 7 Stock Picks to Play the Post-Pandemic Return of Dental Vis...
3 Safe Stocks to Buy That Are Crushing the Market
They perhaps, not so coincidentally, are all in the pharmaceutical business.
Why McKesson Shares Are Jumping Today
McKesson Corp (NYSE: MCK) reported Q4 FY22 adjusted EPS of $5.83, +15% Y/Y, and missing the consensus of $6.04. Revenues increased 12% Y/Y to $66.10 billion, surpassing the consensus of $63.61 billion.
McKesson (MCK) Q4 Earnings Miss, Revenues Beat Estimates
McKesson's (MCK) fiscal fourth-quarter 2022 results benefit from segmental growth.
McKesson (MCK) Lags Q4 Earnings Estimates
McKesson (MCK) delivered earnings and revenue surprises of -3.80% and 3.74%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
McKesson Reports Fiscal 2022 Fourth-Quarter Results
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) has released its fiscal 2022 fourth-quarter financial results. Results can be accessed on McKesson's Investor Relations website at invest...
Medical Product Stocks' Earnings May 5 Roster: MCK, CAH & PODD
The Medical Product companies' quarterly results are likely to reflect base business recovery. Let's see how MCK, CAH and PODD are poised ahead of their earnings releases.
Distributors Agree to Opioid Settlement With Washington State
CONSHOHOCKEN, Pa. & DUBLIN, Ohio & IRVING, Texas--(BUSINESS WIRE)--AmerisourceBergen (NYSE: ABC), Cardinal Health (NYSE: CAH) and McKesson (NYSE: MCK) announced today that they have reached an agreement...
McKesson (MCK) Earnings Expected to Grow: Should You Buy?
McKesson (MCK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
McKesson Declares Quarterly Dividend
IRVING, Texas--(BUSINESS WIRE)--The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of 47 cents per share of common stock. The dividend will be payable on Jul...
McKesson (MCK) Hits 52-Week High: What's Aiding the Stock?
Investors are optimistic about McKesson's (MCK) strength in its Biologics business.
10 Stocks That Have Moved Over 20% Since The Indices Lost Over 12%!
The start of 2022 saw a decline in the stock market. For seasoned investors, this was not unexpected, as corrections in the market are commonplace from January through to March.
Bet on These 4 Low-Beta, High-Dividend MedTech Stocks for 2022
Stocks like Becton, Dickinson and Company (BDX), Phibro Animal Health (PAHC), McKesson Corporation (MCK) and UnitedHealth Group Inc (UNH) are right picks with strong fundamentals.
5 Dividend Growth Stocks for Safe Income Amid Volatility
The Kroger (KR), NVIDIA (NVDA), Jones Lang LaSalle (JLL), Paychex (PAYX) and McKesson (MCK) could be compelling picks amid market volatility.
Why McKesson (MCK) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
McKesson's Board of Directors Elects W. Roy Dunbar as New Director
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) announced today that the McKesson board of directors has elected W. Roy Dunbar as director and member of the Audit and Governance Committ...
3 Lucrative Stocks From the Promising Dental Supplies Industry
Despite the COVID-19 pandemic-induced challenges, teledentistry coupled with AI & Robotics should lend support to the Zacks Medical - Dental Supplies industry. MCK, WST and CAH are well-poised to gain f...
McKesson (MCK) Soars to 52-Week High, Time to Cash Out?
McKesson (MCK) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Should Value Investors Consider McKesson (MCK) Stock Now?
Let's see if McKesson (MCK) stock is a good choice for value-oriented investors right now from multiple angles.
McKesson (MCK) Is Up 6.34% in One Week: What You Should Know
Does McKesson (MCK) have what it takes to be a top stock pick for momentum investors? Let's find out.
Here's Why You Should Buy McKesson (MCK) Stock Right Now
McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.
U.S. should review drugmakers' opioid settlement tax breaks - House panel
The U.S. Justice and Treasury Departments should review the tax deductions four drugmakers made related to their $26 billion opioid settlement, the U.S. House Oversight and Reform Committee said in a st...